After Considering Patients’ Well-being, Rubraca Continues to Benefit Women with Recurrent Ovarian Cancer, Analysis Shows

After Considering Patients’ Well-being, Rubraca Continues to Benefit Women with Recurrent Ovarian Cancer, Analysis Shows
Maintenance therapy with Rubraca (rucaparib) tablets continues to benefit women with recurrent ovarian cancer after weighing in patients' perceptions about their health, disease symptoms, and treatment toxicity, a retrospective analysis of Clovis Oncology's ARIEL3 Phase 3 clinical trial found. The data were presented recently at the International Society for Pharmacoeconomics and Outcomes (ISPOR) 2019 Meeting in New Orleans, Louisiana, in the poster "Patient-Centered Outcomes in ARIEL3, a Phase 3, Randomized, Placebo-Controlled Study of Rucaparib Maintenance Treatment in Patients with Recurrent Ovarian Carcinoma." ARIEL3 is a Phase 3 clinical trial (NCT01968213) showing that maintenance with Rubraca extended the time women lived without disease worsening from 5.4 months to 10.8 months, representing a 64% reduction in the risk of disease progression or death. The trial enrolled 564 women with high-grade, recurrent ovarian carcinoma, who had responded to platinum-based chemotherapy but whose cancer came back. Of these patients, 375 were assigned Rubraca, given as 600 mg tablets twice daily, and 189
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *